CLDX vs. RIOT, MYGN, NTLA, NEOG, QDEL, LNTH, TGTX, AMN, LFST, and TNDM
Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Riot Platforms (RIOT), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Neogen (NEOG), QuidelOrtho (QDEL), Lantheus (LNTH), TG Therapeutics (TGTX), AMN Healthcare Services (AMN), LifeStance Health Group (LFST), and Tandem Diabetes Care (TNDM).
Celldex Therapeutics (NASDAQ:CLDX) and Riot Platforms (NASDAQ:RIOT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Celldex Therapeutics received 104 more outperform votes than Riot Platforms when rated by MarketBeat users. Likewise, 74.84% of users gave Celldex Therapeutics an outperform vote while only 67.21% of users gave Riot Platforms an outperform vote.
Celldex Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Riot Platforms has a beta of 4.25, indicating that its stock price is 325% more volatile than the S&P 500.
40.3% of Riot Platforms shares are owned by institutional investors. 3.7% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Riot Platforms shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Riot Platforms has a net margin of -17.62% compared to Celldex Therapeutics' net margin of -2,054.46%. Riot Platforms' return on equity of 0.89% beat Celldex Therapeutics' return on equity.
Riot Platforms has higher revenue and earnings than Celldex Therapeutics. Riot Platforms is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 78.28%. Riot Platforms has a consensus target price of $18.87, indicating a potential upside of 58.86%. Given Celldex Therapeutics' higher possible upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than Riot Platforms.
In the previous week, Riot Platforms had 21 more articles in the media than Celldex Therapeutics. MarketBeat recorded 23 mentions for Riot Platforms and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.29 beat Riot Platforms' score of 0.15 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Summary
Riot Platforms beats Celldex Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Celldex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celldex Therapeutics Competitors List
Related Companies and Tools
